CA2491313A1 - Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use - Google Patents

Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use Download PDF

Info

Publication number
CA2491313A1
CA2491313A1 CA002491313A CA2491313A CA2491313A1 CA 2491313 A1 CA2491313 A1 CA 2491313A1 CA 002491313 A CA002491313 A CA 002491313A CA 2491313 A CA2491313 A CA 2491313A CA 2491313 A1 CA2491313 A1 CA 2491313A1
Authority
CA
Canada
Prior art keywords
composition
intraocular implant
glyceryl
coo
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002491313A
Other languages
French (fr)
Other versions
CA2491313C (en
Inventor
Bhagwati P. Kabra
Janet D. Howie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon, Inc.
Bhagwati P. Kabra
Janet D. Howie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc., Bhagwati P. Kabra, Janet D. Howie filed Critical Alcon, Inc.
Publication of CA2491313A1 publication Critical patent/CA2491313A1/en
Application granted granted Critical
Publication of CA2491313C publication Critical patent/CA2491313C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets

Abstract

Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.< /SDOAB>

Claims (25)

1. An intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <=37 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2m+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n'H2n+1-2m', -COO-Na+, -COO-K+, -SO3H, -SO3-Na+, -SO3-K+, -NH2, -Cl, n, n' and n" are independently 0 - 50; and m, m' and m" are independently 0 - 10.
2. The intraocular implant composition of Claim 1 wherein the composition is solid or semi-solid at temperatures <=34 °C.
3. The intraocular implant composition of Claim 1 wherein the molecular weight of the lipophilic compound of formula (I) is <=2000.
4. The intraocular implant composition of Claim 3 wherein the molecular weight of the lipophilic compound of formula (I) is <=1000.
5. The intraocular implant composition of Claim 1 wherein the composition comprises a mixture of two or more lipophilic compounds of formula (I).
6. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) has a melting point >= 34 °C.
7. The intraocular implant composition of Claim 5 wherein at least one lipophilic compound of formula (1) has a melting point < 34 °C but the mixture has a melting point >= 34 °C.
8. The intraocular implant composition of Claim 1 wherein R1 is, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2 m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, or -OOCC n H2n+1-2m COOC n'H2n+1-2m';
n, n' and n" are independently 0 - 40; and m, m' and m" are independently 0 - 5.
9. The intraocular implant composition of Claim 8 wherein R1 is R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, or -OOCC n H2n+1-2m;
n, n' and n" are independently 0 - 30; and m, m' and m" are independently 0 - 3.
10. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) is selected from the group consisting of diethylene glycol monostearate; propylene glycol monostearate; glyceryl monostearate;
glyceryl monolinoleate; glyceryl monooleate; glyceryl monopalmitate; and mixtures thereof.
11. The intraocular implant composition of Claim 1 wherein the lipophilic compound of formula (I) is selected from the group consisting of: glyceryl monolaurate; glyceryl dilaurate; glyceryl monomyristate; glyceryl dimyristate;

glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate;
glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; glyceryl monobehenate; and glyceryl dibehenate.
12. The intraocular implant composition of Claim 1 wherein the composition comprises at least 10 % (wt.) of the lipophilic compound of formula (I).
13. The intraocular implant composition of Claim 12 wherein the composition comprises at least 30 % (wt.) of the lipophilic compound of formula (1).
14. The intraocular implant composition of Claim 13 wherein the composition comprises at least 50 % (wt.) of the lipophilic compound of formula (I).
15. The intraocular implant composition of Claim 1 wherein the drug is selected from the group consisting of anti-glaucoma agents; anti-infective agents; non-steroidal and steroidal anti-inflammatory agents; growth factors;
immunosuppressant agents; neuroprotectant agents; angiogenesis-inhibiting agents and anti-allergy agents.
16. The intraocular implant composition of Claim 1 wherein the composition further comprises one or more excipients selected from the group consisting of surfactants, preservatives, and stabilizers.
17. The intraocular implant composition of Claim 16 wherein the composition comprises a surfactant selected from the group consisting of tyloxapol;
polysorbate 20; polysorbate 60; and polysorbate 80.
18. The intraocular implant composition of Claim 16 wherein the composition comprises a preservative selected from the group consisting of quaternary ammonium preservatives.
19 19. The intraocular implant composition of Claim 16 wherein the composition comprises a stabilizer selected from the group consisting of chelating agents;
and antioxidants.
20. The intraocular implant composition of Claim 1 wherein the composition is fashioned into a cylindrical, conical and spherical shape.
21. A method of delivering an ophthalmically acceptable drug to the eye comprising the steps of (a) preparing an intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <=34 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n' H2n+1-2m', -COO- Na+, -COO- K+, -SO3H, -SO3-Na+, - SO3-K+, -NH2, -Cl, n, n' and n" are independently 0 - 50; and m, m' and m" are independently 0 - 10;
and (b) implanting the composition prepared in step (a) in the eye.
22. The method of Claim 21 wherein in step (b) the composition prepared in step (a) is implanted in a site selected from the group consisting of the conjunctiva) cul-de-sac; punctum; lacrimal canaliculus; anterior segment;
posterior segment; sub-Tenon's space; suprachoroidal space; and subconjunctival space.
23. The method of Claim 21 wherein the composition is warmed to a temperature above room temperature and administered through a cannula.
24. The method of Claim 21 wherein the composition is administered as a solid or semi-solid.
25. The method of Claim 21 wherein the intraocular implant composition of step (a) is suspended in a liquid carrier and implanted in the eye in step (b) by administration through a cannula.
CA2491313A 2002-07-15 2003-06-30 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use Expired - Fee Related CA2491313C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39584002P 2002-07-15 2002-07-15
US60/395,840 2002-07-15
PCT/US2003/020707 WO2004006890A1 (en) 2002-07-15 2003-06-30 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use

Publications (2)

Publication Number Publication Date
CA2491313A1 true CA2491313A1 (en) 2004-01-22
CA2491313C CA2491313C (en) 2011-05-24

Family

ID=30115932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2491313A Expired - Fee Related CA2491313C (en) 2002-07-15 2003-06-30 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use

Country Status (18)

Country Link
US (2) US7678827B2 (en)
EP (1) EP1521573B1 (en)
JP (1) JP4463681B2 (en)
KR (1) KR101003518B1 (en)
CN (1) CN100355455C (en)
AT (1) ATE382330T1 (en)
AU (1) AU2003248777B2 (en)
BR (1) BR0312635A (en)
CA (1) CA2491313C (en)
CY (1) CY1107166T1 (en)
DE (1) DE60318446T2 (en)
DK (1) DK1521573T3 (en)
ES (1) ES2295647T3 (en)
MX (1) MXPA05000632A (en)
PL (1) PL206594B1 (en)
PT (1) PT1521573E (en)
WO (1) WO2004006890A1 (en)
ZA (2) ZA200410096B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947015B2 (en) * 1999-01-25 2011-05-24 Atrium Medical Corporation Application of a therapeutic substance to a tissue location using an expandable medical device
US6955661B1 (en) * 1999-01-25 2005-10-18 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
DK1521573T3 (en) * 2002-07-15 2008-03-25 Alcon Inc Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP5097883B2 (en) * 2004-09-02 2012-12-12 株式会社 神崎高級工機製作所 Hydraulic drive vehicle
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006037080A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Uv cured gel and method of making
WO2007034140A1 (en) * 2005-09-21 2007-03-29 Aston University Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
TWI498136B (en) * 2007-10-09 2015-09-01 Alcon Res Ltd An injection device for delivering a rate and temperature-dependent substance into the eye and method of preparing the same
TWI451862B (en) * 2007-10-09 2014-09-11 Alcon Res Ltd Thermal coefficient driven drug pellet size for ophthalmic injection
JP2010104632A (en) 2008-10-31 2010-05-13 Hoya Corp Ophthalmic composition having gelling ability
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8372036B2 (en) * 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
CN102724951A (en) 2009-11-09 2012-10-10 阿勒根公司 Compositions and methods for stimulating hair growth
BR112012017737A8 (en) * 2009-12-22 2018-04-17 Lts Lohmann Therapie Systeme Ag polyvinylpyrrolidone for stabilizing a solid dispersion of the non-crystalline form of rotigotine.
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
DE102011016277B4 (en) 2011-04-06 2013-02-21 Heraeus Medical Gmbh Plastic deformable, biodegradable hemostyptic and method of molding such
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
CN105451731B (en) * 2013-09-26 2019-01-18 参天制药株式会社 Water-based composition containing stabilized 2- amino -3- (4- benzoyl bromide) phenylacetic acid
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
WO2018064648A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
JP7128846B2 (en) 2017-06-13 2022-08-31 アルコン インコーポレイティド intraocular lens composition
RU2675691C1 (en) * 2017-09-14 2018-12-21 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Method of long-term perfusion of subtenon space with medicines

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
JPS6042766B2 (en) * 1978-12-09 1985-09-25 日本化薬株式会社 Base
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
US5015474A (en) * 1988-11-22 1991-05-14 Parnell Pharmaceuticals, Inc. Composition for imparting moisture to a substrate
JPH05500203A (en) * 1989-02-17 1993-01-21 ザ リポソーム カンパニー,インコーポレイテッド Lipid vehicles for intranasal delivery and topical application
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5474780A (en) 1990-04-27 1995-12-12 Allergan, Inc. Monolithic maleic anhydride drug delivery systems
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
ATE195417T1 (en) * 1991-05-13 2000-09-15 Boots Co Plc PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN SALT
US5629019A (en) * 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
WO1994005257A1 (en) 1992-09-08 1994-03-17 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773021A (en) 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
CA2119109C (en) 1994-03-15 2002-11-12 Florian Gurtler Bioadhesive ophthalmic insert
CA2187353C (en) 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
CA2204789C (en) 1994-11-10 2002-11-12 Paul Ashton Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO1997018817A1 (en) 1995-11-20 1997-05-29 Kiyoshi Kita External preparation containing vitamin d or vitamin k
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
EP0973502A1 (en) * 1997-03-12 2000-01-26 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
CA2300154C (en) 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
IL121647A (en) * 1997-08-28 2001-07-24 Pharmateam Dev Ltd Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6099853A (en) * 1997-09-04 2000-08-08 Protein Express Vaginal suppository vaccine for urogenital infections
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
DE19804310A1 (en) * 1998-02-04 1999-08-05 Aventis Res & Tech Gmbh & Co Spiro compounds and their use
DE10030378A1 (en) * 2000-06-21 2002-03-14 Audit Inst For Medical Service New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble active ingredients
WO2001097832A1 (en) * 2000-06-21 2001-12-27 Audit Institute For Medical Services And Quality Assurance Gmbh Pharmaceutical preparations containing cyclosporines and neutral oils
PE20030828A1 (en) 2002-03-04 2003-11-04 Novartis Ag OPHTHALMIC COMPOSITION INCLUDING ASCOMYCIN
DK1521573T3 (en) * 2002-07-15 2008-03-25 Alcon Inc Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors

Also Published As

Publication number Publication date
KR101003518B1 (en) 2010-12-30
AU2003248777A1 (en) 2004-02-02
CN100355455C (en) 2007-12-19
US20080241224A1 (en) 2008-10-02
ZA200410096B (en) 2006-07-26
KR20050023409A (en) 2005-03-09
BR0312635A (en) 2005-04-19
ATE382330T1 (en) 2008-01-15
US8178576B2 (en) 2012-05-15
DE60318446T2 (en) 2008-05-21
PL206594B1 (en) 2010-08-31
PL374743A1 (en) 2005-10-31
PT1521573E (en) 2008-02-08
US20040013704A1 (en) 2004-01-22
CY1107166T1 (en) 2012-10-24
CN1668277A (en) 2005-09-14
CA2491313C (en) 2011-05-24
DE60318446D1 (en) 2008-02-14
US7678827B2 (en) 2010-03-16
MXPA05000632A (en) 2005-03-31
DK1521573T3 (en) 2008-03-25
EP1521573B1 (en) 2008-01-02
JP4463681B2 (en) 2010-05-19
AU2003248777B2 (en) 2008-02-14
ES2295647T3 (en) 2008-04-16
ZA200410095B (en) 2006-07-26
JP2006500328A (en) 2006-01-05
WO2004006890A1 (en) 2004-01-22
EP1521573A1 (en) 2005-04-13

Similar Documents

Publication Publication Date Title
CA2491313A1 (en) Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
JP2006500328A5 (en)
CA2703000C (en) Water-immiscible materials as vehicles for drug delivery
ES2561083T3 (en) Intracameral implants of sustained release therapeutic agents
US20060018949A1 (en) Injectable biodegradable drug delivery system
US8980839B2 (en) Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
US20060210604A1 (en) Ocular delivery of polymeric delivery formulations
JP2019534867A (en) Composition comprising a cannabinoid receptor binding ligand
KR20080011310A (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
US20090118262A1 (en) Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery
JP2022541874A (en) Microemulsion composition
AU2008310956A1 (en) Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
CA2491312A1 (en) Bioerodible film for ophthalmic drug delivery
KR20080011311A (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
CA2146006C (en) Use of ergoline derivatives for the treatment of glaucoma
Khoobehi et al. Clearance of fluorescein incorporated into microspheres from the cornea and aqueous after subconjunctival injection
RU2787998C1 (en) Microemulsion compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180703